Novel allogeneic CAR T-cell platform involving microhomology-mediated end joining repair and low off-targeting potential
{{output}}
Several allogeneic chimeric antigen receptor (CAR) T-cell therapies in clinical trials rely on CRISPR-Cas genome editing, but the enzyme's random repair mechanism increases the risk of undesired off-target effects, challenging safe CAR T-cell generation. To a... ...
